arrow
J

Joaquim Bellmunt

Hospital del Mar Research Institute
H指数:106
被引数:6.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis

基于条件复发和进展无进展生存的浅表性膀胱癌动态预后:一项SEER-医疗保险分析

2026-01-010
PRE
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

高级泌尿肿瘤共识会议(AUC3)2025:肾细胞癌和尿路肿瘤管理的专家共识

2025-12-130
OAAI
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

在恩沃利单抗之后的尿路上皮癌患者中,萨cituzumab govitecan的疗效:UNITE研究的分析

2025-12-010
OAAI
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort

在铂类化疗和帕博利珠单抗治疗后的转移性尿路上皮癌中恩沃利单抗维得尼单抗的疗效:ARON-2EV队列的多中心真实世界分析

2025-11-030
OAAI
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study

FGFR3突变型晚期尿路上皮癌中,erdafitinib在enfortumab vedotin治疗前或治疗后的疗效:UNITE协作研究的分析

2025-11-010
PRE
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

TROPiCS-04研究的通俗语言摘要:沙西妥珠单抗在铂类化疗和免疫疗法之后,用于患有膀胱、尿道或上尿路局部晚期或转移性癌症的人群

2025-11-011
PRE
A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non–muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial

一种使用RUTI疫苗的新型异源初始-加强策略,以改善非肌肉浸润性膀胱癌患者中卡介苗(Bacillus Calmette-Guérin)的应答:RUTIVAC-1试验(Phase 1)

2025-10-140
OAAI
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

接受恩沃利单抗维多汀治疗的晚期尿路上皮癌患者中的治疗相关不良事件及关联结局:UNITE研究的分析

2025-10-020
OAAI
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

ctDNA指导下的辅助阿特珠单抗治疗在肌肉浸润性膀胱癌中的应用

2025-10-0110
PRE
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey

指导晚期尿路上皮癌一线治疗决策:一项全球调查

2025-10-010
OAAI
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study

恩福妥单抗(Enfortumab Vedotin)在具有不同组织学亚型的晚期尿路上皮癌患者中的疗效:UNITE研究的分析

2025-09-140
PRE
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
2025-03-140
OAAI
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial

Sacituzumab govitecan在晚期尿路上皮癌中的应用:TROPiCS-04,一项III期随机试验

2025-02-014
PRE